Favipiravir drug shows promise against Chandipura virus in preclinical studies by NIV
Favipiravir
has been found to have the potential to provide substantial protection against the
Chandipura virus
in the
preclinical studies
conducted by the Pune-based National Institute of Virology(NIV).
The Chandipura virus (CHPV) is endemic in central India and symptoms include high fever and seizures. The infection also induces encephalitis.
Studies on mice have shown that Favipiravir can reduce viral load and improve survival rates in infected animals, Dr Naveen Kumar, Director of NIV, which is under the Indian Council of Medical Research (
ICMR
), told PTI.
The virus was identified during 1965 in Maharashtra from clinical samples of febrile cases.
The first significant outbreak was recorded in 2003 in Telangana, which was then part of Andhra Pradesh. It infected over 300 children with more than 50 per cent fatality.
Live Events
Cases were also reported from Vidarbha region of Maharashtra, Telangana and Gujarat between 2003 and 2007.
Even 2007 onwards sporadic cases from endemic regions were reported.
In 2024, a major outbreak was reported from Gujarat and adjoining areas of Maharashtra which the WHO described as the largest outbreak in the past 20 years.
It emerged to be a major threat for the paediatric population with 64 laboratory confirmed cases of the infection reported from Gujarat (61 cases) and adjoining areas, Dr Vijay Bondre, senior scientist at NIV, said.
The outbreak was investigated by the National Joint Outbreak Response Team, Dr Bondre said.
"The NIV has been working toward identifying potential anti-virals against CHPV. In the search after testing multiple anti-virals, Favipiravir has been identified to give substantial protection against the Chandipura virus infection which has also been established in the preclinical trials in the laboratory," explained Dr Kumar.
So far the findings suggest that Favipiravir could be a potential therapeutic option for these infections, he said.
"Clinical trials on humans are yet to be carried out to confirm its efficacy and safety in humans," Dr Kumar stated.
Dr Bondre said before proceeding to testing on human, the efficacy of the drug against CHPV on animals will be re-established at another organisation - ICMR-National Animal Research Facility for Biological research. This will take another seven to eight months.
Currently, the infection is managed through symptomatic treatment and there is no particular drug which is used for its treatment.
In addition to it, the NIV has initiated research to develop a vaccine candidate against CHPV. The research will be of great help to the nation to minimise the high fatality due this infection among children, Dr Kumar said.
The CHPV is a member of Rhabdoviridae family and is transmitted by arthropod vectors, most probably sand flies. Vector control, hygiene and awareness are the only measures available against the disease.
The disease affects mostly children under 15 years of age and can present with a febrile illness that may progress to convulsions, coma and in some cases may result in death, Dr Bondre said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
an hour ago
- NDTV
US Suspends Visas For Gazans Seeking Medical Aid After Far-Right Campaign
The US government said Saturday it is suspending visitor visas for Gazans after a far-right influencer with the ear of President Donald Trump complained that wounded Palestinians had been allowed to seek medical treatment in the United States. The announcement came one day after a series of furious social media posts by Laura Loomer, who is known for promoting racist conspiracy theories and claiming that the 9/11 terrorist attacks were an inside job. "All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days," the State Department, which is led by Marco Rubio, wrote on X. In a series of posts on X Friday, Loomer called on the State Department to stop giving visas to Palestinians from Gaza who she said were "pro-HAMAS... affiliated with the Muslim Brotherhood and funded by Qatar," without providing evidence. Loomer's target was the US-based charity HEAL Palestine, which said last week it had helped 11 critically wounded Gazan children -- as well as their caregivers and siblings -- arrive safely in the US for medical treatment. It was "the largest single medical evacuation of injured children from Gaza to the US," the charity said on its website. 'Dangerous and inhumane' "Truly unacceptable," Loomer wrote in another X post. "Someone needs to be fired at @StateDept when @marcorubio figures out who approved the visas." "Qatar transported these GAZANS into the US via @qatarairways," she said. Qatar is "literally flooding our country with jihadis," she added. Loomer said she had spoken to the staff of Republican Tom Cotton, who chairs the Senate intelligence committee, adding that they were "also looking into how these GAZANS got visas to come into the US." Republican Congressman Randy Fine explicitly commended Loomer after the visa change was announced, in a sign of her sway over some US policy. "Massive credit needs to be given to @LauraLoomer for uncovering this and making me and other officials aware. Well done, Laura," Fine wrote on X. The Palestine Children's Relief Fund, a US-based charity, called on the Trump administration to "reverse this dangerous and inhumane decision." Over the last 30 years the charity has evacuated thousands of Palestinian children to the US for medical care, it said a statement. "Medical evacuations are a lifeline for the children of Gaza who would otherwise face unimaginable suffering or death due to the collapse of medical infrastructure in Gaza." Though Loomer holds no official position, she wields significant power, and is reported to have successfully pushed for the dismissal of several senior US security officials she deemed disloyal to Trump. In July, Loomer took aim at a job offer made to a highly qualified Biden-era official for a prestigious position at the West Point military academy. The Pentagon rescinded the offer one day later. Trump also fired the head of the highly sensitive National Security Agency, Timothy Haugh, and his deputy Wendy Noble in April at the apparent urging of Loomer, after she met with the president at the White House. "No other content creator or journalist has gotten as many Biden holdovers fired from the Trump admin!" Loomer posted on X Saturday.
NDTV
5 hours ago
- NDTV
Chinese Scientists Working On Robot That Could Give Birth To Human Baby, Prototype To Launch In 2026
Chinese scientists have been working on the world's first "gestation robot", which could give birth to a live baby, The Telegraph reported. The experts have claimed that the technology will imitate a pregnancy from conception to delivery. The fetus is expected to grow inside an artificial womb and receive nutrients through a tube. However, the scientists haven't revealed the specifics on exactly how the egg and sperm will be fertilised. The robot is being developed by Guangzhou-based Kaiwa Technology, led by Dr Zhang Qifeng, who is a scientist from Nanyang Technological University in Singapore. If successful, the technology could potentially assist infertile couples or individuals who prefer not to undergo biological pregnancy. Dr Zhang has claimed the technology is already in a "mature stage". As quoted by the media outlet, he added, "Now it needs to be implanted in the robot's abdomen so that a real person and the robot can interact to achieve pregnancy, allowing the fetus to grow inside." A prototype of the robot is expected to be launched in 2026, with an estimated cost of around 100,000 yuan (approximately $14,000 USD). The technology has sparked debate about ethical implications, including concerns about fetal-maternal bonding, sourcing of eggs and sperm, and psychological impact on the child. Meanwhile, the technology is expected to revolutionise reproductive science and provide new options for individuals facing infertility challenges, which affects approximately 15 per cent of couples globally. The concept builds on existing artificial womb research, including a 2017 experiment where premature lambs were grown in a "biobag" filled with synthetic amniotic fluid. As per the report, Dr Zhang's team is engaging with Guangdong Province authorities on policy and legislation to address legal and ethical questions surrounding the technology.
News18
8 hours ago
- News18
Organ Donation Myths, Realities And The Future Of Kidney Transplants In India
According to Indian Council of Medical Research, 10.1 crore Indians are diabetic. WHO estimates that around 2.5 crore Indians are prediabetic at high risk of developing diabetes We are currently facing a silent epidemic of non-communicable diseases (NCDs), with diabetes mellitus (DM) leading the charge. According to the ICMR (Indian Council of Medical Research), 10.1 crore Indians are diabetic. The WHO estimates that around 2.5 crore Indians are prediabetic at high risk of developing diabetes. Hypertension, or high blood pressure, is also extremely common, affecting an estimated 22–23% of Indians. Together, these two silent diseases are the leading causes of chronic kidney disease (CKD). Various researchers have pegged the prevalence of CKD in India between 10–17%, and these numbers are alarming. Dr Tanmay Pandya, HOD & Director, Nephrology & Renal Transplantation, Sarvodaya Hospital, Sector-8, Faridabad shares all you need to know: While CKD spans a broad spectrum, the most dreaded stage is kidney failure, also known as End-Stage Kidney Disease (ESKD), where most patients require kidney replacement therapy. In India, over 3 lakh new patients are diagnosed with ESKD annually and require some form of kidney replacement therapy. Globally, available options include either dialysis or kidney transplantation. Considering quality of life, life expectancy, and financial impact, kidney transplantation is clearly the preferred modality especially in the resource-limited settings of India. For transplantation, the foremost requirement is a donor kidney. This may come from organ donation at the time of brain death, or, more commonly in India, from another person. In our society, owing to several reasons, donation from a living, related donor is the primary source of kidneys for transplantation. The process is governed by the Transplantation of Human Organs Act, passed by Parliament and implemented across states and union territories. Humans have two kidneys working seamlessly as a single unit, providing one of the most efficient organ systems in the body. Remarkably, if one kidney is removed for some reason, the other can largely compensate. For a healthy person, the impact of removing one kidney is negligible. This forms the rationale for kidney donation from a living donor. Several studies have addressed the health implications of organ donation and concluded that the practice is safe when the donor is carefully selected. One calculation shows the risk of developing CKD after donation is only 0.24% higher compared to non-donors, a minuscule, medically and ethically acceptable number. Similarly, living liver donation is also largely safe, as the liver can regenerate the donated segment within months, leaving practically no long-term impact. That said, living donors do face short- and long-term risks, primarily related to surgery. Donor selection is therefore a meticulous, rigorous process involving multi-speciality consultation and a battery of investigations to ensure safety. Only when a donor is deemed fit is the donation approved. Post-surgery, recovery is similar to other major operations. Most donors can return to routine activities within two weeks, though heavy physical work should be avoided for a while longer. Donors are counselled to adopt a healthier lifestyle, including regular exercise, balanced nutrition, and complete avoidance of smoking and alcohol. Periodic health checkups are mandatory to ensure long-term safety. Despite its safety, the donor pool remains small for any given patient. Generally, only close relatives are accepted as donors, but incompatibility such as mismatched blood groups or tissue types often creates challenges. Treatments exist to overcome these incompatibilities, but they come with added costs and risks. An innovative solution is kidney swap transplantation. In this system, two or more donor–recipient pairs are matched to overcome incompatibility and achieve successful transplantation. Swap transplants are legally permitted in most Indian states, and organisations like the Indian Society of Organ Transplantation (ISOT) and the National Organ & Tissue Transplantation Organisation (NOTTO) actively promote them. Multi-way swaps sometimes involving up to 10 pairs have been successfully performed in India. Institutions such as IKDRC, Ahmedabad, routinely conduct 100–150 swap transplants per year. ISOT has also developed software to help doctors find suitable matches. Swap transplantation has thus emerged as a life-saving alternative in kidney transplantation in India, significantly expanding the donor pool and utilising available donors more effectively. First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
